Contradictory KRAS mutation test results in a patient with metastatic colon cancer: A clinical dilemma in the era of personalized medicine

The KRAS oncogene is mutated in 40‒50% of colorectal cancers and confers resistance to EGFR-targeted therapy. In the clinic, agents such as cetuximab or panitumumab target the EGFR receptor for therapeutic benefit. Cetuximab was approved by the FDA in 2012 as first-line therapy for KRAS mutation-neg...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Lamparella, Nicholas E, Saroya, Bikramajit S, Yang, Zhaohai, Sarwani, Nabeel E, El-Deiry, Wafik S
Médium: Artigo
Jazyk:Inglês
Vydáno: Landes Bioscience 2013
Témata:
Bedside to Bench Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841208/
https://ncbi.nlm.nih.gov/pubmed/23792572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.25095
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky